Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Schnabel

Showing results (31-40 of 46) with videos related to

Pageof 5
Sort By:
Antibiotics (Basel, Switzerland)|October 25, 2024
Amoxicillin/Clavulanic Acid in Transrectal Biopsy of the Prostate-An Alternative in Times of Ciprofloxacin Obsolescence and Fosfomycin Limitation?Philipp J Spachmann, Sophie E Fischer, Christopher Goßler, et al.
Nucleic Acids Research|July 10, 1981
The nucleotide sequence of Euglena cytoplasmic phenylalanine transfer RNA. Evidence for possible classifications of Euglena among the animal rather than the plant kingdomS H Chang, L I Hecker, C K Brum, et al.
Brain Research|January 13, 1992
Postinjury scopolamine administration in experimental traumatic brain injuryB G Lyeth, M Ray, R J Hamm, et al.
Cancers|June 24, 2022
Efficacy of Vinflunine for Patients with Metastatic Urothelial Cancer after Immune Checkpoint Inhibitor Pretreatment-A Retrospective Multicenter AnalysisFelix Riedel, Mara Münker, Florian Roghmann, et al.
Cancers|June 22, 2023
Patient's Desire and Real Availability Concerning Supportive Measures Accompanying Radical Prostatectomy: Differences between Certified Prostate Cancer Centers and Non-Certified Centers Based on Patient-Reported Outcomes within the Cross-Sectional Study ImproveIngmar Wolff, Martin Burchardt, Julia Peter, et al.
Urologic Oncology|February 21, 2026
Progression-free survival with darolutamide and docetaxel vs. androgen receptor pathway inhibitors vs. docetaxel in metastatic hormone-sensitive prostate cancer: A real-world multicenter retrospective studyEmily Rinderknecht, Gloria Bielstein, Richard Cathomas, et al.
Future Oncology (London, England)|May 24, 2022
Targeting <i>FGFR3</i> alterations with adjuvant infigratinib in invasive urothelial carcinoma: the phase III PROOF 302 trialSumanta K Pal, Diederik M Somford, Petros Grivas, et al.
Current Oncology (Toronto, Ont.)|November 26, 2024
Modification and Validation of the System Causability Scale Using AI-Based Therapeutic Recommendations for Urological Cancer Patients: A Basis for the Development of a Prospective Comparative StudyEmily Rinderknecht, Dominik von Winning, Anton Kravchuk, et al.
European Urology Oncology|December 11, 2025
Benchmarking Large Language Models Against Multidisciplinary Tumor Boards in Urological Oncology: Results from the Blinded, Prospective CONCORDIA StudyEmily Rinderknecht, Maximilian Haas, Marco J Schnabel, et al.
The Journal of Biological Chemistry|October 9, 2001
Structural basis for pterin antagonism in nitric-oxide synthase. Development of novel 4-oxo-pteridine antagonists of (6R)-5,6,7,8-tetrahydrobiopterinP Kotsonis, L G Fröhlich, C S Raman, et al.
Pageof 5

Showing results (31-40 of 46) with videos related to

Sort By:
Pageof 5
Antibiotics (Basel, Switzerland)|October 25, 2024
Amoxicillin/Clavulanic Acid in Transrectal Biopsy of the Prostate-An Alternative in Times of Ciprofloxacin Obsolescence and Fosfomycin Limitation?Philipp J Spachmann, Sophie E Fischer, Christopher Goßler, et al.
Nucleic Acids Research|July 10, 1981
The nucleotide sequence of Euglena cytoplasmic phenylalanine transfer RNA. Evidence for possible classifications of Euglena among the animal rather than the plant kingdomS H Chang, L I Hecker, C K Brum, et al.
Brain Research|January 13, 1992
Postinjury scopolamine administration in experimental traumatic brain injuryB G Lyeth, M Ray, R J Hamm, et al.
Cancers|June 24, 2022
Efficacy of Vinflunine for Patients with Metastatic Urothelial Cancer after Immune Checkpoint Inhibitor Pretreatment-A Retrospective Multicenter AnalysisFelix Riedel, Mara Münker, Florian Roghmann, et al.
Cancers|June 22, 2023
Patient's Desire and Real Availability Concerning Supportive Measures Accompanying Radical Prostatectomy: Differences between Certified Prostate Cancer Centers and Non-Certified Centers Based on Patient-Reported Outcomes within the Cross-Sectional Study ImproveIngmar Wolff, Martin Burchardt, Julia Peter, et al.
Urologic Oncology|February 21, 2026
Progression-free survival with darolutamide and docetaxel vs. androgen receptor pathway inhibitors vs. docetaxel in metastatic hormone-sensitive prostate cancer: A real-world multicenter retrospective studyEmily Rinderknecht, Gloria Bielstein, Richard Cathomas, et al.
Future Oncology (London, England)|May 24, 2022
Targeting <i>FGFR3</i> alterations with adjuvant infigratinib in invasive urothelial carcinoma: the phase III PROOF 302 trialSumanta K Pal, Diederik M Somford, Petros Grivas, et al.
Current Oncology (Toronto, Ont.)|November 26, 2024
Modification and Validation of the System Causability Scale Using AI-Based Therapeutic Recommendations for Urological Cancer Patients: A Basis for the Development of a Prospective Comparative StudyEmily Rinderknecht, Dominik von Winning, Anton Kravchuk, et al.
European Urology Oncology|December 11, 2025
Benchmarking Large Language Models Against Multidisciplinary Tumor Boards in Urological Oncology: Results from the Blinded, Prospective CONCORDIA StudyEmily Rinderknecht, Maximilian Haas, Marco J Schnabel, et al.
The Journal of Biological Chemistry|October 9, 2001
Structural basis for pterin antagonism in nitric-oxide synthase. Development of novel 4-oxo-pteridine antagonists of (6R)-5,6,7,8-tetrahydrobiopterinP Kotsonis, L G Fröhlich, C S Raman, et al.
Pageof 5